Chronic hepatitis C: Treatments of the future

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue , 2011, Pages S84-S95

  Bourlière, Marc ^a   Khaloun, Asma ^a   Wartelle Bladou, Claire ^b   Oules, Valérie ^a   Portal, Isabelle ^a   Benali, Souad ^a   Adhoute, Xavier ^a   Castellani, Paul ^a  

^a HÔPITAL SAINT JOSEPH   (France)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ARTICLE; DRUG COMBINATION; FORECASTING; HEPATITIS C; HUMAN;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FORECASTING; HEPATITIS C, CHRONIC; HUMANS;

MLCS; MLOWN;

EID: 84862740452     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/S2210-7401(11)70013-4     Document Type: Article

References (67)

1. Poordad, F., McCone, J. Jr., Bacon, B.R., Bruno, S., Manns, M.P., Sulkowski, M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364 (2011), 1195–1206.
2. Jacobson, I.M., McHutchison, J.G., Dusheiko, G., Di Bisceglie, A.M., Reddy, K.R., Bzowej, N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364 (2011), 2405–2416.
3. Bacon, B.R., Gordon, S.C., Lawitz, E., Marcellin, P., Vierling, J.M., Zeuzem, S., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364 (2011), 1207–1217.
4. Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 364 (2011), 2417–2428.
5. Sherman, K.E., Flamm, S.L., Afdhal, N.H., Nelson, D.R., Sulkowski, M.S., Everson, G.T., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365 (2011), 1014–1024.
6. Foster, G.R., Hézode, C., Bronowicki, J.P., Carosi, G., Weiland, O., Verlinden, L., et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141 (2011), 881–890.
7. Benhamou, Y., Moussalli, J., Ratziu, V., Lebray, P., De Backer, K., Ghys, A., et al. Activity of telaprevir or in combination with peginterferon alfa-2a and ribavirin in treatment naive genotype 4 hepatitis C patients. Final results of study C210 (Abstact). Hepatology 52:Suppl 1 (2010), 719–720A.
8. Silva, M., Kasserra, C., Gupta, S., Treitel, M., Hughes, E., O'Mara, E., Antiviral activity of boceprevir monotherapy in treatmentnaive subjects with chronic hepatitis C genotype 2/3. Hepatol Int, 5, 2011, 229.
9. C—esek, S., von Hahn, T., Manns, M.P., Second-wave protease inhibitors: choosing an heir. Clin Liver Dis 15 (2011), 597–609.
10. Fusco, D.N., Chung, R.T., New protease inhibitors for HCV–help is on the way. J Hepatol 54 (2011), 1087–1089.
11. Asselah, T., Marcellin, P., New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int 31:Suppl 1 (2011), 68–77.
12. Fried, M., Buti, M., Dore, G.J., Flisiak, R., Ferenci, P., Jacobson, I.M., et al. TMC 435 in combination with peginterferonand ribavirin in treatment naive HCV genotype 1 patients: Final results of the PILLAR phase IIB study (Abstract). Hepatology, 54(Suppl 1), 2011, 1429A.
13. Zeuzem, S., Foster, G.R., Fried, M.W., Hezode, C., Hirschfield, G.M., Nikitin, I., et al. The ASPIRE trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who havec failed previous PEGIFN/RBV treatment (Abstract). J Hepatol, 54(Suppl 1), 2011, S546.
14. Sulkowski, M., Ceasu, E., Asselah, T., Caruntu, F.A., Lalezari, J., Ferenci, P., et al. Silen-C1: sustained virologic response and safety of BI201335 combined with peginterferon alfa-2a and ribavirin in treatment naive patients with chronic genotype 1 infection (Abstract). J Hepatol, 54(Suppl 1), 2011, S27.
15. Sulkowski, M., Bourliere, M., Bronowicki, J.P., Streinu-Cercel, A., Preotescu, L., Asselah, T., et al. SILEN-C2: Sustained virologic response and safety of BI 201335 combined with peginterferon alfa-2A and ribavirin in chronic HCV genotype 1 patients with non-response to P/R (Abstract). J Hepatol, 54(Suppl 1), 2011, S30.
16. Terrault, N., Cooper, C., Balan, L.A., Larrey, D., Box, T.D., Yoshida, E.M., et al. Phase II randomized, partially-blind, parallel-group study of oral danoprevir (RG7227) with pegIFN alfa-2a plus ribavirin in treatment-naive genotype 1 patients with CHC: results of planned week 12 interim analysis of the ATLAS study (Abstract). Hepatology, 52(Suppl 1), 2010, 335A.
17. Rouzier, R., Larrey, D., Gane, E.J., Wiercinska-Drapalo, A., Chang, L., Zhang, Y., et al. Activity of danoprevir plus low-dose ritonavir in combination with peginterferon alfa-2A plus ribavirin in previous null responders (Abstract). J Hepatol, 54(Suppl 1), 2011, S28.
18. Manns, M., Gane, E.J., Rodriguez-Torres, M., Stoehr, A.D., Yeh, C.T., Marcellin, P., et al. Sustained viral response rates in genotype 1 treatment-naive patients with chronic hepatitis C infection treated with Vaniprevir (MK7009), a NS3/4A protease inhibitor, in combination with pegylated interferon alfa-2A and ribavirin for 28 days (Abstract). Hepatology, 52(Suppl 1), 2010, 361A.
19. Lawitz, E., Rodriguez-Torres, M., Stoehr, A., Gane, E.J., Serfaty, L., Bhanja, S., et al. A phase 2B study of MK 7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment (Abstract). Hepatology 54:Suppl 1 (2011), 1434–1435A.
20. Lawitz, E., Gaultier, I., Poordad, F., Dejesus, E., Kowdley, K., Sepulveda, G., et al. 4-week virologic response and safety of ABT-450 given with low-dose ritonavir (ABT-450/R) in combination with pegylated interferon alpha-2a and ribavirin (SOC) after 3-day monotherapy in genotype 1 (GT1) HCV-infected treatment-naïve subjects (Abstract). Hepatology 52:Suppl 1 (2010), 878–879.
21. Lalezari, J.P., Hazan, L., Kankam, M., Lawitz, E., Poordad, F., Araya, V., et al. High rapid virologic response with ACH-1625 daily dosing plus peginterferon alpha-2a/RBV in a 28 day phase 2A trial (Abstract). Hepatology, 54(Suppl 1), 2011, 992A.
22. Lok, A.S., Gardiner, D., Lawitz, E., Martorell, C., Everson, G., Ghalib, R., et al. Quadriple therapy with BMS-790052, BMS-650032 and peg-IFN/RBV for 24 weeks results in 100% SVR 12 in HCV genotype 1 null-responders (Abstract). J Hepatol, 54(Suppl 1), 2011, S536.
23. Zeuzem, S., Buggisch, P., Agarwal, K., Manns, M., Marcellin, P., Foster, G., et al. Dual, triple and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naive genotype 1 HCV subjects (Abstract). Hepatology, 52(Suppl 1), 2010, 400A.
24. Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, et al. The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C. Hepatology 2011, in press.
25. Brainard, D.M., Petry, A., Van Dyck, K., Nachbar, R.B., De Lepeleire, I.M., Caro, L., et al. Safety and antiviral activity of MK-5172 a novel HCV NS3/4A protease inhibitors with potent activity against known resistance mutants in genotype 1 and 3 HCV-infected patients (Abstract). Hepatology 52:Suppl 1 (2010), 706–707.
26. Membreno, F.E., Lawitz, E.J., The HCV, NS5B nucleoside and nonnucleoside inhibitors. Clin Liver Dis 15 (2011), 611–626.
27. Jensen, D.M., Wedemeyer, H., Herring, R.W., Ferenci, P., Ma, M.M., Zeuzem, S., et al. High rate of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV G1/4 patients treated with RG7128 plus pegIFN alfa-2A/RBV: planned week 12 interim analysis from the PROPEL study (Abstract). Hepatology, 52(Suppl 1), 2010, 360A.
28. Pockros, P., Jensen, D., Tsai, N., Taylor, R.M., Ramji, A., Cooper, C., et al., First SVR, data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment naive HCV G1/4 patients: interim analysis from the JUMP-C trial (Abstract). J Hepatol, 54(Suppl 1), 2011, S538.
29. Gane, E.J., Rodriguez-Torres, M., Nelson, D.E., Jacobson, I.M., McHutchinson, J.G., Duca, A., et al. Sustained virologic response following RG7128 1500 mg BID/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non responders (Abstract). J Hepatol, 52(Suppl 1), 2010, S16.
30. Lalezari, J., Lawitz, E., Rodriguez-Torres, M., Sheikh, A., Freilich, B., Nelson, D.R., et al. Once daily PSI-7977 plus PEGIFN/RBV in a phase 2B trial: Rapid virologic suppression in treatment-naive patients with HCV GT2/GT3 (Abstract). J Hepatol, 54(Suppl 1), 2011, S28.
31. Gane, E.J., Stedman, C., Hyland, R.H., Sorensen, R.D., Symonds, W.T., Hindes, R., et al. Once daily PSI-7977 plus RBV: Pegylated interferon alfa not required for complete rapid viral response in treatment naive patients with HCV GT2 or GT3 (Abstract). Hepatology, 54(Suppl 1), 2011, 377A.
32. Lawitz, E., Lalezari, J., Hassanein, T., Kowdley, K.V., Poordad, F.F., Sheikh, A.M., et al. Once daily PSI-7977 plus PEG/RBV in treatment naive patients with HCV GT1: Robust end of treatment response rates are sustained post treatment (Abstract). Hepatology, 54(Suppl 1), 2011, 472A.
33. Larrey, D., Lohse, A., de Ledinghen, V., Trepo, C., Gerlach, J.T., Zarski, J.P., et al. 4 week therapy with the non nucleosidic polymerase inhibitor BI 207127 in combination with peginterferon alfa-2A and ribavirin in treatment naive and treatment-experienced chronic HCV GT1 patients (Abstract). J Hepatol, 52(Suppl 1), 2010, S466.
34. Jacobson, I., Pockros, P.J., Lalezari, J., Lawitz, E., Rodriguez-Torres, M., Dejesus, E., et al. Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa-2A and ribavirin in chronically-infected HCV genotype-1 patients (Abstract). J Hepatol, 52(Suppl 1), 2010, S465.
35. Di Bisceglie, A.M., Nelson, D.R., Gane, E., Alves, K., Koziel, M.J., De Souza, C., et al. VX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment naive patients with chronic hepatitis C: ZENITH study interim results (Abstract). J Hepatol, 54(Suppl 1), 2011, S540.
36. Rodriguez-Torres, M., Lawitz, E., Conway, B., Kaita, K., Sheikh, A.M., Ghalib, R., et al. Safety and antiviral activity of the HCV nonnucleoside polymerase inhibitor VX-222 in treatment-naive genotype 1 HCV infected patients (Abstract). J Hepatol, 52(Suppl 1), 2010, S14.
37. Lawitz, E., Rodriguez-Torres, M., Rustgi, V.K., Hassanein, T., Rahimy, M.H., Crowley, C.A., et al. Safety and antiviral activity of ANA 598 in combination with pegylated interferon alfa-2A plus ribavirin in treatment-naive genotype 1 chronic HCV patients (Abstract). Hepatology 52:Suppl 1 (2010), 334–335.
38. Rodriguez-Torres, M., Lawitz, E., Cohen, D., Larsen, L., Menon, R.M., Collins, C., al. E. Treatement naive genotype 1 HCV infected subjects shiw significantly greater HCV RNA decreases when treated 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone (Abstract). Hepatology, 50(Suppl 4), 2009, LB6.
39. Lawitz, E., Jacobson, I., Godofsky, E., Foster, G.R., Flisiak, R., Bennett, M., et al. A phase 2 B trial comparing 24 to 48 weeks treatment with tegobuvir (GS-9190)/PEG/RBV to 48 weeks tretament with PEG/RBV for chronic genotype 1 HCV infection (Abstract). J Hepatol, 54(Suppl 1), 2011, S181.
40. Gish, R.G., Meanwell, N.A., The NS5A replication complex inhibitors: difference makers?. Clin Liver Dis 15 (2011), 627–639.
41. Pol, S., Ghalib, R.H., Rustgi, V.K., Martorell, C., Everson, G.T., Tatum, H.A., et al. First report of SVR 12 for NS5A replication complex inhibitor BMS-790052 in combination with PEG-IFN and RBV: Phase 2A trial in treatment naive HCV-genotype 1 subjects (Abstract). J Hepatol 54:Suppl 1 (2011), S544–S545.
42. Ahn, J., Flamm, S.L., Hepatitis C, therapy: other players in the game. Clin Liver Dis 15 (2011), 641–656.
43. Flisiak, R., Horban, A., Gallay, P., Bobardt, M., Selvarajah, S., Wiercinska-Drapalo, A., et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47 (2008), 817–826.
44. Flisiak, R., Feinman, S.V., Jablkowski, M., Horban, A., Kryczka, W., Pawlowska, M., et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49 (2009), 1460–1468.
45. Flisiak, R., Pawlostky, J.M., Crabbe, R., Calistru, P.I., Kryczka, W., Haussinger, D., et al. Once daily alisporivir (DEBIO25) plus PEGIFN alfa-2A/ribavirin results in superior sustained virologic response in chronic hepatitis C genotype-1 treatment naive patients (Abstract). J Hepatol, 54(Suppl 1), 2011, S2.
46. Pawlostky, J.M., Flisiak, R., Rasenack, J., Sarin, S.K., Piratvisuth, T., Chuang, W.L., et al. Once daily alisporivir interferon-free regimens achieve high rates of early HCV clearance in previously untreated patients with HCV genotype 2 or 3 (Abstract). Hepatology, 54(Suppl 1), 2011, 1433A.
47. Lawitz, E., Godofsky, E., Rouzier, R., Marbury, T., Nguyen, T., Ke, J., et al. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Res 89 (2011), 238–245.
48. Hopkins, S., Scorneaux, B., Huang, Z., Murray, M.G., Wring, S., Smitley, C., et al. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother 54 (2010), 660–672.
49. Rossignol, J.F., Kabil, S.M., El-Gohary, Y., Elfert, A., Keeffe, E.B., Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 28 (2008), 574–580.
50. Rossignol, J.F., Elfert, A., El-Gohary, Y., Keeffe, E.B., Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136 (2009), 856–862.
51. Habersetzer, F., Baumert, T.F., Stoll-Keller, F., GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther 11 (2009), 456–462.
52. McHutchinson, J., Goodman, Z.D., Everson, G.T., Jacobson, I.M., Boyer, T.D., Schiff, E.R., et al. GI-5005 therapeutic vaccine plus peg-interferon/ribavirin improves biopsy necro-inflammatory scores and ALT normalization at 48 weeks versus peginterferon/ribavirin in genotype 1 chronic HCV patients (Abstract). J Hepatol, 52(Suppl 1), 2010, S116.
53. Matti Salberg, M., Frelin, L., Diepolder, H., Jung, M.C., Mathiesen, I., Fons, M., et al. A first clinical trial of therapeutic vaccination using nake DNA delivered by in vivo electoporation shows antiviral effects in patients with chronic hepatitis C (Abstract). J Hepatol 50:Suppl 1 (2009), S18–S19.
54. Wedemeyer, H., Schuller, E., Schlaphoff, V., Stauber, R.E., Wiegand, J., Schiefke, I., et al. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 27 (2009), 5142–5151.
55. Klade, C.S., Wedemeyer, H., Berg, T., Hinrichsen, H., Cholewinska, G., Zeuzem, S., et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 134 (2008), 1385–1395.
56. Wedemeyer, H., Janczewska-Kazek, E., Mazur, W.W., Stanciu, C., Habersetzer, F., Carreno, V., et al. HCVac study: antiviral activity of TG4040 therapeutic vaccine in genotype 1 chronic HCV patients (Abstract). Hepatology, 54, 2011, 989A.
57. Ahmed-Belkacem, A., Ahnou, N., Barbotte, L., Wychowski, C., Pallier, C., Brillet, R., et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 138 (2010), 1112–1122.
58. Polyak, S.J., Morishima, C., Shuhart, M.C., Wang, C.C., Liu, Y., Lee, D.Y., Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology 132 (2007), 1925–1936.
59. Eurich, D., Bahra, M., Berg, T., Boas-Knoop, S., Biermer, M., Neuhaus, R., et al. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. Exp Clin Transplant 9 (2011), 1–6.
60. Zeuzem, S., Arora, S., Bacon, B., Box, T., Charlton, M., Diago, M., et al. Pegylated interferon lambda shows superior viral response with improved safety and tolerability versus PegIFN alfa-2A in HCV patients (G1/2/3/4): EMERGE phase IIB through week 12 (Abstract). J Hepatol 54:Suppl 1 (2011), S538–S539.
61. Everson, G.T., Gray, T.E., Hillson, J.L., Horga, M., Xu, D., Fontana, D., et al. Pegylated interferon lambda ameliorates ribavirin-induced anemia in HCV patients by maintaining compensatory erythropoiesis: analysis of emerge phase 2B results through week 12, (Abstract). Hepatology 54:Suppl 1 (2011), 993–994.
62. Rodriguez-Torres, M., Hillson, J.L., Bacon, B.R., Box, T.D., Hassanein, T., Greenbloom, S., et al. Safety and efficacy of pegylated interferon lambda compared to pegylated interferon alfa-2a in HCV-infected patients G1/2/3 wih compensated cirrhosis: EMERGE phase 2b efficacy and safety results through week 12 (Abstract). Hepatology, 54(Suppl 1), 2011, 994A.
63. Olsen, D.B., Davies, M.E., Handt, L., Koeplinger, K., Zhang, N.R., Ludmerer, S.W., et al. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob Agents Chemother 55 (2011), 937–939.
64. Gane, E.J., Roberts, S.K., Stedman, C.A., Angus, P.W., Ritchie, B., Elston, R., et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376 (2010), 1467–1475.
65. Zeuzem, S., Asselah, T., Angus, P., Zarski, J.P., Larrey, D., Müllhaupt, B., et al. Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection. Gastroenterology 141 (2011), 2047–2055.
66. Zeuzem, S., Asselah, T., Angus, P.W., Zarski, J.P., Larrey, D., Müllhaupt, B., et al. High sustained virologic response following interferonfree treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor BI 201335, polymerase inhibitor BI 207127 and ribavirin followed by BI 201335 and PEGIFN/ribavirin-The SOUND-C1 study (Abstract). Hepatology 54:Suppl 1 (2011), 486–487A.
67. Di Bisceglie, A.M., Nelson, D.R., Gane, E., Alves, K., Koziel, M.J., De Souza, C., et al. VX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment naive patients with chronic hepatitis C: ZENITH study interim results (Abstract). J Hepatol, 54(Suppl 1), 2011, S540.